score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594N	0.0586	324.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.D594N (Missense)	1.0	MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.R367Q	0.0631	111.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143													0				GATA3 p.R367Q (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat103		
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P254S	0.1138	290.0	2.5e-05	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.P254S (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.H106Y	0.05	100.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0				JAK1 p.H106Y (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.S274F	0.0385	260.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				RAD54L p.S274F (Missense)	0.0	MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.K757R	0.0515	136.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				CDK12 p.K757R (Missense)	0.0	MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P1094L	0.165	206.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0				PBRM1 p.P1094L (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P1094S	0.1626	203.0	8e-06	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0				PBRM1 p.P1094S (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P1167L	0.0431	255.0	0.0	0.0																					0				MTOR p.P1167L (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P217S	0.0606	66.0	0.0	0.0																					0				TACC3 p.P217S (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P591L	0.0581	86.0	0.0	0.0																					0				TACC3 p.P591L (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P696L	0.0223	359.0	0.0	0.0																					0				ROS1 p.P696L (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D401N	0.06	150.0	7.4e-05	0.0																					0				NTRK3 p.D401N (Missense)		MEL-IPI_Pat103	MEL-IPI_Pat103-Tumor-SM-4CU6Q	MEL-IPI_Pat103-Normal-SM-53U4P
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.77																									0				COSMIC Signature (version 2) 7 (77%)		MEL-IPI_Pat103		
